Cidara Therapeutics Inc. (CDTX): How investors can get the most out of their investments – Invest Chronicle

Cidara Therapeutics Inc. (CDTX): How investors can get the most out of their investments

For the readers interested in the stock health of Cidara Therapeutics Inc. (CDTX). It is currently valued at $0.46. When the transactions were called off in the previous session, Stock hit the highs of $0.60, after setting-off with the price of $0.60. Company’s stock value dipped to $0.4121 during the trading on the day. When the trading was stopped its value was $0.59.Recently in News on May 11, 2022, Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results. Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its corporate activities and product pipeline. You can read further details here

Cidara Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.4100 on 01/03/22, with the lowest value was $0.4121 for the same time period, recorded on 05/12/22.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Cidara Therapeutics Inc. (CDTX) full year performance was -77.23%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cidara Therapeutics Inc. shares are logging -80.75% during the 52-week period from high price, and -19.65% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.57 and $2.39.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1160748 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Cidara Therapeutics Inc. (CDTX) recorded performance in the market was -63.78%, having the revenues showcasing -44.73% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 31.98M, as it employees total of 89 workers.

The Analysts eye on Cidara Therapeutics Inc. (CDTX)

During the last month, 0 analysts gave the Cidara Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.8663, with a change in the price was noted -0.99. In a similar fashion, Cidara Therapeutics Inc. posted a movement of -68.28% for the period of last 100 days, recording 348,609 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CDTX is recording 0.12 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of Cidara Therapeutics Inc. (CDTX)

Raw Stochastic average of Cidara Therapeutics Inc. in the period of last 50 days is set at 7.39%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 10.69%. In the last 20 days, the company’s Stochastic %K was 9.26% and its Stochastic %D was recorded 17.58%.

Considering, the past performance of Cidara Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -63.78%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -69.93%, alongside a downfall of -77.23% for the period of the last 12 months. The shares increased approximately by -40.75% in the 7-day charts and went down by -39.36% in the period of the last 30 days. Common stock shares were lifted by -44.73% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts